CC-93538 for Eosinophilic Esophagitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the ongoing safety and tolerability of CC-93538 in participants who were part of earlier studies involving this treatment.
Do I need to stop my current medications to join the trial?
The trial requires that you do not take certain medications, such as systemic immunosuppressive drugs or oral immunotherapy, before and during the study. If you are on these medications, you may need to stop them to participate.
How is the drug CC-93538 different from other treatments for eosinophilic esophagitis?
What data supports the effectiveness of the drug CC-93538 for Eosinophilic Esophagitis?
While there is no direct data on CC-93538, similar treatments like omalizumab and dupilumab have shown some effectiveness in reducing inflammation and symptoms in eosinophilic esophagitis and other eosinophilic disorders. Omalizumab reduced inflammation in some patients, and dupilumab helped achieve remission in patients with eosinophilic gastrointestinal disorders.45678
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults and adolescents who have Eosinophilic Esophagitis (EoE) and were part of previous CC-93538 studies. They must not have other conditions that could affect the study, no severe allergies to ingredients in CC-93538, no recent immunotherapy or live vaccines, and women must test negative for pregnancy and use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CC-93538 subcutaneously once weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue to receive CC-93538 to evaluate long-term safety and tolerability
What Are the Treatments Tested in This Trial?
Interventions
- CC-93538
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania